Guo's Endovascular Aortic Arch Replacement of Aortic Dissection by WeFlow-Tribranch Endoprothesis: a Multicenter Pilot Study(GRAFT Study)

Exclusion Criteria

• •1. Patients that have experienced systemic infection during past three months;
• •2. Neck surgery was performed within three months;
• •3. Infectious aortic disease、Takayasu arteritis，Marfan syndrome (or other connective tissue diseases );
• •4. Patients with severe stenosis, calcification, thrombosis or tortuosity of the Brachiocephalic trunk, Left common carotid artery or left subclavian artery;
• •5. Heart transplant patients;
• •6. Patients that have suffered MI or stroke during past three months;
• •7. Patients with Class IV heart function (NYHA classification) or LVEF\<30%
• •8. Active peptic ulcers or upper gastrointestinal bleeding occurring within the previous three months;
• •9. Hematological abnormality, defined as follows: Leukopenia (WBC \< 3 × 109/L), acute anemia (Hb \< 90 g/L); thrombocytopenia (PLT count \< 50 × 109/L);
• •10. Patients with renal insufficiency， serum creatinine \> 150 umol/l (or 3.0 mg/dl) and / or end-stage renal disease requiring renal dialysis shall be determined by the investigator after comprehensive analysis;
• •11. Subjects with severe liver dysfunction and ALT or AST exceeding 3 times the upper limit of normal; Subjects whose serum total bilirubin (STB) exceeds 2 times the upper limit of normal;
• •12. Patients with intestinal necrosis and lower limb ischemic necrosis;
• •13. Paraplegic patients;
• •14. Patients that are pregnant or breastfeeding;
• •15. Patients with allergies to contrast agents;
• •16. Patients with a life expectancy of less than 12 months;
• •17. Patients currently participating in other drug or device research;
• •18. Any other disease or abnormality that the investigators believe may hinder endovascular interventional treatment.